Related Experiment Video
Updated: Jun 7, 2026
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Impact of statin use on heart failure mortality
Senthil K Thambidorai1, Anand R Deshmukh, Ryan W Walters
1Department of Cardiovascular Medicine, Creighton University, Omaha, NE 68131, USA.
Insights
Statin therapy significantly reduces all-cause mortality in heart failure patients. Consistent statin use, even short-term, provides a survival benefit, while no statin use increases mortality risk.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Conflicting data exists on statin therapy's mortality benefit in heart failure patients.
- Understanding the impact of statin duration on outcomes is crucial.
Purpose of the Study:
- To determine if statin therapy is associated with decreased all-cause mortality in heart failure patients.
- To assess the effect of incremental duration of statin therapy on mortality.
Main Methods:
- A cohort of 10,510 Veterans Affairs patients with heart failure was studied from 2002-2006.
- Patients were categorized by statin use duration (none, 1-25%, 26-75%, >75%).
- Logistic regression and Kaplan-Meier methods analyzed the association between statin use and all-cause mortality.
Main Results:
- Statin use demonstrated a significant association with decreased all-cause mortality in heart failure patients.
- The mortality benefit was observed within one year of initiating statin therapy.
- Patients with less than 25% statin use showed no significant mortality benefit.
Conclusions:
- Veterans not exposed to statins had a 1.56 times higher likelihood of all-cause mortality.
- Statin therapy appears to offer a mortality benefit in heart failure, with duration being a key factor.
Background:
There is conflicting data regarding the mortality benefit of statins in patients with heart failure. The objectives of our study were to determine whether statin therapy is associated with decreased all-cause mortality and to assess the effect of incremental duration of therapy.
Methods:
We studied 10,510 consecutive patients from the Veterans Affairs health system with a diagnosis of heart failure from January 2002 through December 2006. Mean follow-up was 2.66 years. Statin use and duration of therapy were identified. Veterans were classified into four groups based on duration of statin use during the study period (none, 1-25%, 26-75% and >75% use of statins). Logistic regression was performed to identify the association between incident statin use and all-cause mortality following a diagnosis of heart failure. The Kaplan-Meier method was employed to assess for differences in survival time between the four statin use classifications.
Results:
Statin use was significantly associated with decreased all-cause mortality following a diagnosis of heart failure after controlling for age, gender, concurrent medications and comorbid diagnoses [χ(3)(2) (N = 10,510) = 1077.82, p < 0.001]. The benefit was seen within a relatively short duration (within 1 year) after starting statins, and in patients with <25% use of statins, there was no mortality benefit.
Conclusion:
Veterans who were not exposed to statin therapy at any time during the study period were 1.56 times more likely to suffer all-cause mortality.
Related Concept Videos
01:22Heart Failure Drugs: β-Blockers
01:30Heart Failure V: Medical Management
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:30Heart Failure IV: Classification and Diagnostic Evaluation
01:27Heart Failure I: Introduction
01:30Heart Failure VII: Nursing Interventions